157 related articles for article (PubMed ID: 19551467)
1. Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
Vamos E; Voros K; Zadori D; Vecsei L; Klivenyi P
J Neural Transm (Vienna); 2009 Sep; 116(9):1079-86. PubMed ID: 19551467
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
Vamos E; Voros K; Vecsei L; Klivenyi P
Biomed Pharmacother; 2010 Apr; 64(4):282-6. PubMed ID: 19932584
[TBL] [Abstract][Full Text] [Related]
3. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
[TBL] [Abstract][Full Text] [Related]
5. High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice.
Molnár MF; Török R; Szalárdy L; Sümegi E; Vécsei L; Klivényi P
Acta Neurobiol Exp (Wars); 2016; 76(3):176-81. PubMed ID: 27685770
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
7. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
8. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
[TBL] [Abstract][Full Text] [Related]
9. Animal models of Huntington's disease: from basic research on neuronal death to assessment of new therapeutic strategies.
Brouillet E
Funct Neurol; 2000; 15(4):239-51. PubMed ID: 11213527
[No Abstract] [Full Text] [Related]
10. Towards a transgenic model of Huntington's disease in a non-human primate.
Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
[TBL] [Abstract][Full Text] [Related]
11. The use of transgenic and knock-in mice to study Huntington's disease.
Hickey MA; Chesselet MF
Cytogenet Genome Res; 2003; 100(1-4):276-86. PubMed ID: 14526189
[TBL] [Abstract][Full Text] [Related]
12. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
[TBL] [Abstract][Full Text] [Related]
13. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
[TBL] [Abstract][Full Text] [Related]
14. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
[TBL] [Abstract][Full Text] [Related]
16. Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
[TBL] [Abstract][Full Text] [Related]
17. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine.
Grote HE; Bull ND; Howard ML; van Dellen A; Blakemore C; Bartlett PF; Hannan AJ
Eur J Neurosci; 2005 Oct; 22(8):2081-8. PubMed ID: 16262645
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
[TBL] [Abstract][Full Text] [Related]
19. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
20. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
